ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Rossari Biotech achieved its highest-ever quarterly revenue of Rs. 697.2 crore and EBITDA of Rs. 80.6 crore in Q1 FY27, driven by 28% YoY top-line growth and international expansion.
Rossari Biotech filed its quarterly shareholding pattern for the quarter ended June 30, 2026. The filing notes a change in residential status for a promoter group member.
Rossari Biotech Limited announced the appointment of Mr. Udeypaul Singh Gill and the re-appointment of Ms. Esha Padmanabhan Achan as Non-Executive Independent Directors.
Rossari Biotech Limited held its 17th Annual General Meeting on July 20, 2026. All resolutions proposed in the AGM notice were passed with the requisite majority.
Rossari Biotech reported Q1 FY27 consolidated revenue of ₹697.2 crore, up 28% YoY. It also established a new 5,000 MTPA greenfield blending facility in Thailand.
Rossari Biotech reported record Q1 FY27 revenue of Rs. 697.2 cr (up 28.2% YoY) and EBITDA of Rs. 80.6 cr (up 18.7% YoY), driven by strong demand across core HPPC and TSC segments.
Rossari Biotech is selling its wholly-owned subsidiary, Rossari International Limited Company, to its Singapore subsidiary for approximately ₹24 Crore. This internal restructuring completes by March 2027.
Rossari Biotech allotted equity shares under its Employee Stock Option Plan - 2019. This adjustment increases the company's issued share capital.
Rossari Biotech's board approved unaudited quarterly financial results, granted 4,000 ESOP options, allotted 2,500 equity shares, and restructured overseas subsidiaries via share transfer to Rossari Singapore.
Rossari Biotech will hold a board meeting on July 18, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.